Literature DB >> 20826917

Diagnostic and prognostic utility of PD-1 in B cell lymphomas.

S Muenst1, S Hoeller, N Willi, S Dirnhofera, A Tzankov.   

Abstract

AIMS: Programmed death-1 (PD-1) is expressed by germinal center-associated helper T-cells and acts as a negative regulator of the immune system. PD-1 is encountered on tumor cells of angioimmunoblastic T-cell lymphoma and is a postulated diagnostic marker in chronic lymphocytic leukemia (CLL/SLL). Recent data suggest prognostic importance of PD-1 in follicular lymphoma (FL). We assessed the diagnostic potential and the prognostic importance of PD-1 in B-cell lymphomas.
METHODS: Distribution of PD-1+ lymphocytes in B-cell lymphomas was studied on 403 cases. Correlation with known biologic and clinical key data was performed. Prognostic cut-off scores were determined by receiver operating curve analysis.
RESULTS: PD-1+ tumor-infiltrating lymphocytes were numerous in extranodal marginal zone lymphomas and FL. Their amount decreased from FL grade 1 to grade 3 and to FL with transformation to diffuse large B-cell lymphoma. An increased amount of PD-1 tumor-infiltrating lymphocytes above the prognostic cut-off score (> 2.8%) was a positive prognostic factor of disease-specific survival (DSS) in FL-patients. Five percent of the studied 66 CLL/SLL cases showed unequivocal PD-1 positivity of neoplastic cells.
CONCLUSIONS: Increased number of PD-1+ tumor-infiltrating lymphocytes is associated with significantly improved DSS in FL and may be useful to predict its heterogeneous clinical behavior. PD-1 has probably limited diagnostic value for primary histopathological CLL/SLL diagnostics.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20826917      PMCID: PMC3835488          DOI: 10.3233/DMA-2010-0725

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  34 in total

1.  High tumoral PD-L1 expression and low PD-1+ or CD8+ tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system.

Authors:  Sehui Kim; Soo Jeong Nam; Changhee Park; Dohee Kwon; Jeemin Yim; Seung Geun Song; Chan-Young Ock; Young A Kim; Sung Hye Park; Tae Min Kim; Yoon Kyung Jeon
Journal:  Oncoimmunology       Date:  2019-06-10       Impact factor: 8.110

Review 2.  Follicular helper T cells: implications in neoplastic hematopathology.

Authors:  Philippe Gaulard; Laurence de Leval
Journal:  Semin Diagn Pathol       Date:  2011-08       Impact factor: 3.464

3.  Plasmablastic Lymphomas: Characterization of Tumor Microenvironment Using CD163 and PD-1 Immunohistochemistry.

Authors:  Janice S Ahn; Ali Al-Habib; Jeffrey A Vos; Aliyah R Sohani; Oralia Barboza-Quintana; Juan P Flores; Sijin Wen; Flavia G Rosado
Journal:  Ann Clin Lab Sci       Date:  2020-03       Impact factor: 1.256

4.  Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

Authors:  Wei Ding; Betsy R LaPlant; Timothy G Call; Sameer A Parikh; Jose F Leis; Rong He; Tait D Shanafelt; Sutapa Sinha; Jennifer Le-Rademacher; Andrew L Feldman; Thomas M Habermann; Thomas E Witzig; Gregory A Wiseman; Yi Lin; Erik Asmus; Grzegorz S Nowakowski; Michael J Conte; Deborah A Bowen; Casey N Aitken; Daniel L Van Dyke; Patricia T Greipp; Xin Liu; Xiaosheng Wu; Henan Zhang; Charla R Secreto; Shulan Tian; Esteban Braggio; Linda E Wellik; Ivana Micallef; David S Viswanatha; Huihuang Yan; Asher A Chanan-Khan; Neil E Kay; Haidong Dong; Stephen M Ansell
Journal:  Blood       Date:  2017-04-19       Impact factor: 22.113

5.  Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy.

Authors:  Thomas Menter; Alexandar Tzankov
Journal:  Virchows Arch       Date:  2018-08-21       Impact factor: 4.064

Review 6.  The emerging role of immune checkpoint inhibition in malignant lymphoma.

Authors:  Ida Hude; Stephanie Sasse; Andreas Engert; Paul J Bröckelmann
Journal:  Haematologica       Date:  2016-11-24       Impact factor: 9.941

Review 7.  Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?

Authors:  Andrew Davies
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 8.  Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?

Authors:  Fabienne McClanahan; Thomas G Sharp; John G Gribben
Journal:  Haematologica       Date:  2016-10       Impact factor: 9.941

9.  EBV infection determines the immune hallmarks of plasmablastic lymphoma.

Authors:  Pauline Gravelle; Sarah Péricart; Marie Tosolini; Bettina Fabiani; Paul Coppo; Nadia Amara; Alexandra Traverse-Gléhen; Nathalie Van Acker; Pierre Brousset; Jean-Jacques Fournie; Camille Laurent
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

10.  Follicular lymphomas in children and young adults: a comparison of the pediatric variant with usual follicular lymphoma.

Authors:  Qingyan Liu; Itziar Salaverria; Stefania Pittaluga; Armin G Jegalian; Liqiang Xi; Reiner Siebert; Mark Raffeld; Stephen M Hewitt; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2013-03       Impact factor: 6.394

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.